India, June 16 -- image credit- freepik

US-based biotech startup Porosome Therapeutics has entered into a drug development partnership with the Council of Scientific and Industrial Research (CSIR).

The goals of the partnership include collaboration, co-development and licensing of new and novel drugs. The CSIR announcement highlighted priority domains for collaboration with Porosome: viral infections, Alzheimer's disease, neurological diseases, cystic fibrosis, Type 1 and 2 diabetes, COPD, and lung cancer.

Porosome Therapeutics has developed a wide range of therapies ranging from small molecules and peptides to biologics that introduce functional porosomes into diseased cells to overcome secretory defects and treat diseases, even rever...